← All organizations
Highest phase reached
Phase 4
Timeline
2000s
- Jun 1, 2006
Ocular Therapeutix, Inc.— Founded
2010s
- Nov 30, 2018
urea— NDA Secondary Org
- Nov 30, 2018
dexamethasone— Marketing Organization
Drugs by trial phase (15 distinct, 47 trials)
Phase 4 (8 own, 0 via acquisition)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Indications
Studied for
- Capsule Opacification
- Cataract
- Conjunctivitis
- Conjunctivitis, Allergic
- Dissociative Disorders
- Dry Eye Syndromes
- Eye Diseases
- Glaucoma
- Glaucoma, Open-Angle
- Hypertension
- Inflammation
- Iridocyclitis
- Keratoconjunctivitis Sicca
- Keratoconus
- Macular Degeneration
- Macular Edema
- Ocular Hypertension
- Postoperative Pain
- Pterygium
- Retinal Detachment
- Retinal Vein Occlusion
- Uveitis
- Uveitis, Anterior
Marketed drugs (2)
Recent trials (47)
- NCT07235085Lead sponsorPhase 3Nov 17, 2025
- NCT06495918Lead sponsorPhase 3Jul 15, 2024
- NCT06223958Lead sponsorPhase 3Jan 29, 2024
- NCT05814757Lead sponsorPhase 2May 11, 2023
- NCT05372315CollaboratorPhase 4Jun 15, 2022
- NCT05335122Lead sponsorPhase 2Mar 16, 2022
- NCT05116345CollaboratorPhase 4Nov 30, 2021
- NCT05143281CollaboratorPhase 4Nov 23, 2021
- NCT04728646CollaboratorPhase 4Sep 30, 2021
- NCT05023304CollaboratorPhase 4Aug 23, 2021
- NCT04989699Lead sponsorPhase 1Jul 28, 2021
- NCT04945824Lead sponsorEarly Phase 1Jun 1, 2021
- NCT04863742CollaboratorPhase 4Apr 26, 2021
- NCT04708821CollaboratorPhase 4Feb 15, 2021
- NCT04747977Lead sponsorPhase 2Feb 12, 2021
Details
- Founded
- Bedford, MA, US Jun 1, 2006
- Last known activity
- Nov 17, 2025